|
2.9 Etiologie - Tabac
|
|
|
|
3. Prévention
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
3.7 Prévention - Alcool
|
|
|
|
Alcohol and cancer [The Lancet]
|
|
|
|
|
|
It
is not unimaginable that bottles of Château Mouton Rothschild, which
once bore the artwork of Salvador Dali and Pablo Picasso, might one day
be required to have plain packaging and images of oesophageal cancer or a
cirrhotic liver.
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
Genomenon Creates Automated, Evidence-Based Cancer Gene Panel [Xconomy]
|
|
|
|
|
|
Genomenon’s
panel was produced using its software tool, the Mastermind Genomic
Search Engine. Mastermind mines millions of medical journal articles to
find associations between genetic mutations and disease, with the goal
of significantly reducing the time doctors spend combing through medical
data and simplifying the process of picking which genes to sequence.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
Experimental Ovarian Cancer Vaccine Shows Promise in Mice [NCI]
|
|
|
|
|
|
The
vaccine used in the study targets the protein AMHR2-ED. This protein is
an example of what one of the study’s lead authors, Vincent Tuohy,
Ph.D., calls a "retired" protein—a protein that is no longer expressed,
or made, in normal body tissues as people age.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
Fighting Cancer One Patient At A Time [Forbes]
|
|
|
|
|
|
Loxo
shares are up 175% so far this year, thanks to the excitement about
larotrectinib and two other rare-cancer medicines it is developing.
Other companies taking the rare-disease approach are doing equally well.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Brexit gets real for drugmakers as regulator moves to Amsterdam [Reuters]
|
|
|
|
|
|
It
will be up to EU governments to decide whether to offer some kind of
mutual recognition system once Britain is out of the EU and no longer
under the remit of the European Court of Justice, which oversees the
EMA. Asked if he expected such future cooperation, Rasi said: “It is
completely unknown.”
|
|
|
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
Bayer’s Stivarga wins NICE approval for GIST [PharmaTimes]
|
|
|
|
|
|
Specifically,
the cost watchdog has ruled that the treatment can be routinely funded
on the NHS to treat unresectable or metastatic GIST in adults whose
disease has progressed on, or who are intolerant to, prior treatment
with imatinib and sunitinib.
|
|
|
|
|
|
|
5.5.5 ASCO (gastro-intestinal)
|
|
|
|
5.8.5 ASH - Myélome multiple
|
|
|
|
|
5.8.6 ASH - Leucémies
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10 Politiques
|
|
|
|
NHS England announces plans to break down barriers for research [NHS England]
|
|
|
|
|
|
NHS
Chief Executive Simon Stevens will announce that proposals to
streamline and standardise the process of setting up trials across
multiple sites, needed to develop treatments for rare cancers and other
complex conditions, and claiming back excess treatment costs that can be
a barrier to innovation will be considered by the NHS England Board
next week.
|
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
|
|
Living With Cancer: Giving Thanks for Survivors [NY Times]
|
|
|
|
|
|
I
have always shunned the identity “cancer survivor.” Wary of language
that obscures the ongoing threat of a mortal disease, I know that I may
not survive cancer; at any moment, it might recur and kill me. Nor can I
take credit for my ongoing life.
|
|
|
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|